ITUS - ANIXA BIOSCIENCES INC

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
    PR Newswire7 months ago

    ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

    SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (ITUS), a biotechnology company focused on using the body's immune system to fight cancer, today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc.  Effective at the start of trading on October 1, 2018, the Company's shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX."  The Company's website will be accessible at www.anixa.com.

  • GuruFocus.com7 months ago

    Weekly CFO Buys Highlight

    Insiders invest in ITUS, Energy Transfer Partners and PolarityTE

  • Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy
    PR Newswire8 months ago

    Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

    SAN JOSE, Calif., Sept. 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018.  The meeting is to discuss numerous aspects of the planned clinical trial of their CAR-T therapy for ovarian cancer. Dr. Amit Kumar, CEO of ITUS stated, "We are pleased to be meeting with the FDA this fall, as anticipated.  We have submitted pre-clinical data, as well as a series of questions, to the FDA.  Coming out of this meeting, our goal is to have a good understanding of the design for the clinical trial in our Investigational New Drug (IND) application.

  • ITUS Corporation to Present at Next Generation Dx Summit
    PR Newswire8 months ago

    ITUS Corporation to Present at Next Generation Dx Summit

    SAN JOSE, Calif., Aug. 17, 2018  /PRNewswire/ -- ITUS Corporation (ITUS) today announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th.  Dr. Kumar's presentation, "Liquid Biopsy based on Flow Cytometry and Artificial Intelligence to Detect the Existence of a Solid Tumor," is scheduled at 2:50 PM EDT, Wednesday, August 22nd.  Dr. Kumar will discuss ITUS's latest data on its Cchek™ diagnostic development, including studies on breast cancer and prostate cancer, as well as data from the collaborative study with Memorial Sloan Kettering and Serametrix.

  • Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy
    PR Newswire9 months ago

    Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy

    This meeting, known as a pre-IND meeting, is designed to enable drug developers and the FDA to evaluate a drug's pre-clinical data and its proposed development path in anticipation of filing an Investigational New Drug (IND) application.  ITUS and Moffitt have previously stated that this program is ahead of schedule.  Assuming the FDA does not require additional animal studies, ITUS and Moffitt hope to file the IND application in early 2019 and begin human trials once approved by the FDA.

  • ITUS Corporation Releases Results for Cchek™ Breast Cancer Study
    PR Newswire9 months ago

    ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

    The Cchek™ breast cancer study is focused on early stage cancer, because other methods are poor at accurately identifying stage 1 and 2 malignancies.  The interim results showed sensitivity of 92% and specificity of 87% for stage 1 and 2 cancers.  The interim data utilized blood samples from a total of 144 patients, that included 64 women who had biopsy verified breast cancer, and 80 women with no cancer.  Our AI application was trained with 88 patients and tested with 56.  As later stage patients are added to the study, performance is expected to improve.

  • ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer
    PR Newswire10 months ago

    ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

    SAN JOSE, Calif. , July 6, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that due to the significance of positive results as well as strong commercial interest, it has selected breast ...

  • ITUS to Ring the NASDAQ Closing Bell on July 5th
    PR Newswire10 months ago

    ITUS to Ring the NASDAQ Closing Bell on July 5th

    ITUS recently announced that the CAR-T therapy for ovarian cancer, being developed in collaboration with The Moffitt Cancer Center, is roughly one year ahead of its original development timeline, and the Company anticipates a pre-IND meeting with the US FDA in the October/November timeframe.  Assuming the FDA does not require significant additional animal studies, the IND application could be filed as soon as Q1 of 2019 with human trials beginning as early as the first half of 2019. The event can be viewed live by visiting https://new.livestream.com/nasdaq/live.

  • ITUS Accelerates Schedule for its CAR T Therapy and Provides Update
    PR Newswire10 months ago

    ITUS Accelerates Schedule for its CAR T Therapy and Provides Update

    SAN JOSE, Calif., June 26, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today provided a status update and accelerated development timeline for its CAR T therapy for Ovarian Cancer, which is in development with Moffitt Cancer Center. ITUS initiated a Cooperative R&D Agreement (CRADA) with Moffitt to advance a proprietary CAR T therapy for ovarian cancer in November 2017.  The study is led by Jose Conejo-Garcia, M.D., Ph.D., Chair of the Department of Immunology at Moffitt.  The aim of this CRADA is to complete the pre-clinical studies necessary for the submission of an IND application to the FDA, seeking approval to test the therapy in human patients.  The previous goal for IND submission was the end of 2019 or early 2020, now it has been accelerated dramatically.

  • ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer
    PR Newswire10 months ago

    ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

    SAN JOSE, Calif. , June 13, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has chosen prostate cancer as the first commercial focus for its Cchek™, non-invasive liquid biopsy ...

  • ACCESSWIRE10 months ago

    ITUS Corp. (ITUS) Stock: A Disruptive Force In Cancer Diagnostics And Immunotherapy

    CORAL SPRINGS, FL / ACCESSWIRE / June 12, 2018 / Cancer is a devastating illness that affects a large population of patients in the United States. In fact, it is estimated by the National Cancer Institute that in the year 2018 alone, 1.73535 million patients will be diagnosed with cancer and 609,640 Americans will succumb to the ailment. At the helm of innovation in the cancer diagnostics and immunotherapy markets, we find ITUS Corp. (NASDAQ: ITUS).

  • ACCESSWIRE11 months ago

    Complimentary Technical Snapshots on Fiserv and Three More Business Services Stocks

    Research reports have been issued by WallStEquities.com on Fiserv Inc. (NASDAQ: FISV), FleetCor Technologies Inc. (NYSE: FLT), Genpact Ltd (NYSE: G), and ITUS Corp. (NASDAQ: ITUS). Companies in the Business Services sector provide support services, such as office administration, hiring and placing of personnel, security services, travel arrangement, cleaning, and waste disposal, to businesses.

  • Who Really Owns ITUS Corporation (NASDAQ:ITUS)?
    Simply Wall St.last year

    Who Really Owns ITUS Corporation (NASDAQ:ITUS)?

    Today, I will be analyzing ITUS Corporation’s (NASDAQ:ITUS) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both its short-Read More...

  • ACCESSWIRElast year

    ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 3 rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8 th at ...